- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01106352
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
November 11, 2016 updated by: Bayer
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and explore efficacy of the recommended dose.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The trial was initially conducted and submitted by Algeta ASA.
After acquiring Algeta, Bayer is now the sponsor.
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Villejuif Cedex, France, 94805
-
-
-
-
California
-
San Francisco, California, United States, 94115
-
-
Illinois
-
Evanston, Illinois, United States, 60201
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115-6013
-
-
New York
-
New York, New York, United States, 10065
-
-
Washington
-
Seattle, Washington, United States, 98109
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Two or more bone metastases (hot spots) confirmed by bone scintigraphy within 8 weeks prior to study entry
- Known castration-resistant disease
- Karnofsky Performance Status (KPS): ≥70% within 14 days before start of study treatment (ECOG 1)
- Life expectancy at least 6 months.
- Acceptable hematology and serum biochemistry screening values
- Eligible for use of docetaxel according to the product information (package insert or similar).
Exclusion Criteria:
- Has received an investigational therapeutic drug within the last 4 weeks prior to start of study treatment, or is scheduled to receive one during the treatment period.
- Has received external radiotherapy within the last 4 weeks prior to start of study treatment.
- Has an immediate need for radiotherapy.
- Has received prior hemibody external radiotherapy .
- Has received systemic radiotherapy (e.g. samarium, strontium etc.) for the treatment of bone metastases.
- Has received cytotoxic chemotherapy within the last 4 weeks prior to start of study treatment, or has not recovered to grade 1 or 0 from adverse events due to cytotoxic chemotherapy administered more than 4 weeks earlier.
- Has received more than ten previous infusions of docetaxel.
- Previous known experience of grade ≥ 3 docetaxel related toxicities or docetaxel toxicity related dose interruption or discontinuation.
- Previous use of G-CSF for persistent neutropenia after docetaxel treatment.
- Has received blood transfusion or erythropoietin (EPO) within the last 4 weeks prior to start of study treatment.
- Has received prior treatment with Alpharadin.
- Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
- Symptomatic nodal disease, i.e. scrotal, penile or leg edema.
- Visceral metastases from CRPC (>2 lung and/or liver metastases [size ≥2cm]), as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to start of study treatment.
- Uncontrolled loco-regional disease.
- Other primary tumor (other than CRPC) including haematological malignancy present within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).
- Has imminent or established spinal cord compression based on clinical findings and/or MRI.
- Unmanageable fecal incontinence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel
Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w.
every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
|
Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
|
Active Comparator: Docetaxel
Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
|
Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Dose-Limiting Toxicities - Dose Escalation Part
Time Frame: From randomization until 6 weeks post-injection in all dose cohort of dose-escalation part
|
DLT was defined as - Absolute neutrophil count grade greater than or equal to (>=) 4 (Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0: less than [<] 0.5 × 109 per Liter) lasting longer than 7 days without fever despite granulocyte colony-stimulating factor (G-CSF) support).
Platelet count Grade >= 4 (CTCAE, v4.0: < 25× 109/L) lasting longer than 7 days.
Diarrhea Grade >= 3 (CTAE, v4.0: increase of >= 7 stools per day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care in activities of daily living) in spite of optimal use of antidiarrheal medication.
Vomiting or constipation Grade >= 4 (CTCAE, v4.0: life-threatening consequences; urgent intervention indicated).
Febrile neutropenia Grade >= 3 (CTCAE, v4.0).
|
From randomization until 6 weeks post-injection in all dose cohort of dose-escalation part
|
Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Treatment-Emergent Serious Adverse Events (TESAE) With a CTCAE Grade of 3 or 4
Time Frame: From start of study treatment to 6 weeks after study treatment (that is maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort) and 8 weeks for serious AEs
|
Treatment-emergent adverse event (TEAEs) were defined as events that occur following the first injection of study treatment, or that started prior to the first injection and worsened during treatment.
An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship.
An Serious Adverse Event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in patient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent adverse events were defined as adverse events/serious adverse events that started or worsened after the study drug treatment.
|
From start of study treatment to 6 weeks after study treatment (that is maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort) and 8 weeks for serious AEs
|
Change From Baseline in Serum Biochemistry (Albumin, Protein, Hemoglobin) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Change From Baseline in Serum Biochemistry (Alkaline Phosphatase [AP], Alanine Aminotransferase [AAT], Lactate Dehydrogenase [LD]) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Change From Baseline in Serum Biochemistry (Bilirubin, Creatinine) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Change From Baseline in Serum Biochemistry (Calcium, Chloride, Magnesium, Potassium, Phosphate, Sodium, Urea) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Change From Baseline in Serum Biochemistry (Platelets, Leukocytes, Lymphocytes, Neutrophils, Monocytes, Eosinophils, Basophils) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Change From Baseline in Serum Biochemistry (Erythrocytes) During the Treatment Period
Time Frame: Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
Baseline, Day 106 (dose escalation period), and Day 190 (expanded safety cohort)
|
Changes From Baseline in Systolic and Diastolic Blood Pressure During the Treatment Period
Time Frame: From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Changes From Baseline in Respiratory Rate During the Treatment Period
Time Frame: From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Changes From Baseline in Heart Rate During the Treatment Period
Time Frame: From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Changes From Baseline in Weight During the Treatment Period
Time Frame: From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
|
From start of study treatment to 6 weeks after study treatment (that is, maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Number of Subjects With Physical Examination During the Treatment Period
Time Frame: From start of study treatment to 6 weeks after study treatment (i.e., maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Any physical examination finding that was classified by the investigator as a clinically significant change (compared with previous examination) was considered an AE, documented on the eCRF, and followed until the outcome was known.
The below physical examination findings were recorded and reported.
GDASC = General disorders and administration site conditions MND = Metabolism and nutrition disorders SSTD= Skin and subcutaneous tissue disorders MCTD = Musculoskeletal and connective tissue disorders IPPC = Injury, poisoning and procedural complications RTMD = Respiratory, thoracic and mediastinal disorders NBMU = Neoplasms benign, malignant and unspecified (include cysts and polyps) In the below table.
|
From start of study treatment to 6 weeks after study treatment (i.e., maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Number of Subjects With Signs of Long-Term Radiation Toxicity
Time Frame: From start of study treatment upto 12 months
|
Long-term radiation toxicity included incidence of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukemia, myelodysplastic syndrome, and aplastic anemia).
|
From start of study treatment upto 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Efficacy: Weighted Mean Area Under the Curve for Bone Turnover Biomarkers
Time Frame: From start of study treatment to 6 weeks after study treatment (maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Weighted mean area under the curve for the below bone turnover biomarkers were evaluated, ICTP = pyridinoline cross-linked carboxyterminal telopeptide P1NP = N-terminal peptide of procollagen type 1 uCTX-1 = urine C-telopeptide 1
|
From start of study treatment to 6 weeks after study treatment (maximum 12 weeks in dose escalation; 30 weeks in the expanded safety cohort)
|
Exploratory Efficacy: Time to Prostate-specific Antigen (PSA) Progression
Time Frame: 12 months
|
Serum PSA progression defined as two consecutive increases in PSA over a previous reference value within 6 months of first study treatment, each measurement at least 1 week apart.
|
12 months
|
Exploratory Efficacy: Percent Change From Baseline in Circulating Tumor Cells at Day 85
Time Frame: Baseline, Day 85, expanded safety cohort
|
CTCs were measured to follow the evolution of the level of CTCs after treatment.
|
Baseline, Day 85, expanded safety cohort
|
Exploratory Efficacy: Time to Clinical or Radiographic Progression
Time Frame: From start of study treatment to 12 months, at every 12 weeks
|
Time to first radiologic or clinical progression is determined by one of the following:
|
From start of study treatment to 12 months, at every 12 weeks
|
Progression Free Survival (PFS) End Point
Time Frame: From start of study treatment to 12 months, at every 12 weeks
|
PFS defined as the time from randomization (randomization referred to the date of treatment assignment) to disease progression (radiological or clinical, whichever was earlier) or death (if death occurred before progression was documented).
Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.
|
From start of study treatment to 12 months, at every 12 weeks
|
Overall Survival Rate
Time Frame: 12 months
|
The overall survival (OS) time in days was calculated as number of days since the day of first dose of study medication until the date of death.
|
12 months
|
Number of Subjects Who Responded to Interactive Voice Response System (IVRS) Pain
Time Frame: From start of study treatment until 12 months
|
The subject completed the full BPI (short form) paper questionnaire, and clinical staff completed the analgesic log.
The test consists of 10 questions addressing severity, location, chronicity, and amount of relief.
In question 3, subjects with pain are asked to evaluate the severity of pain at worst in the past 24 hours in a 0 to 10 scale, with 0 indicating no pain, and 10 indicating the worst pain.
|
From start of study treatment until 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 Jun;114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11.
- Gkialas IK, Fragkoulis C. Emerging therapies targeting castration-resistant prostate cancer. J BUON. 2015 Nov-Dec;20(6):1389-96.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2010
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
April 16, 2010
First Submitted That Met QC Criteria
April 16, 2010
First Posted (Estimate)
April 19, 2010
Study Record Updates
Last Update Posted (Estimate)
January 4, 2017
Last Update Submitted That Met QC Criteria
November 11, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Genital Neoplasms, Male
- Prostatic Diseases
- Musculoskeletal Diseases
- Neoplastic Processes
- Bone Diseases
- Prostatic Neoplasms
- Neoplasm Metastasis
- Bone Neoplasms
- Bone Marrow Diseases
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Radium Ra 223 dichloride
Other Study ID Numbers
- 15469
- BC1-10 (Other Identifier: Algeta ASA)
- 2011-000822-31 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Metastases
-
University of CalgaryNot yet recruitingBone Metastases | Spine Metastases | Bone LesionCanada
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingPatients With Bone MetastasesChina
-
Luye Pharma Group Ltd.RecruitingBone Metastases From Solid TumorsChina
-
Shanghai JMT-Bio Inc.CompletedBone Metastases From Solid TumorsChina
-
Varian, a Siemens Healthineers CompanyRecruitingBone Metastases in the ThoraxUnited States
-
Ottawa Hospital Research InstituteWithdrawn
-
UMC UtrechtCompletedBone Metastases | Spinal MetastasesNetherlands
-
University of Roma La SapienzaCompletedBone Metastases | Secondary Bone CancerItaly
-
Shanghai JMT-Bio Inc.Not yet recruitingImaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
-
Heidelberg UniversityCompletedVertebral Bony MetastasesGermany
Clinical Trials on Radium-223 dichloride (Xofigo, BAY88-8223)
-
BayerActive, not recruitingMetastatic Castration-resistant Prostate CancerUnited States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
-
BayerCompletedProstate CancerUnited States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedProstatic NeoplasmsChina, Singapore, Taiwan, Korea, Republic of
-
BayerCompletedBone Metastatic Castration-resistant Prostate CancerGermany, Netherlands, Denmark
-
BayerCompletedProstatic Neoplasms, Castration-ResistantUnited States